The chemical synthesis of relatively short segments of nucleic acids with defined chemical structure is known as oligonucleotide synthesis. The method is particularly valuable in recent laboratory practice since it allows for quick and low-cost access to custom-made oligonucleotides of the appropriate sequence. The future use of customized therapy to cure chronic illnesses is ideal because to oligonucleotide synthesis.
The global Oligonucleotide Synthesis Linkers market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Oligonucleotide Synthesis Linkers is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Oligonucleotide Synthesis Linkers is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Oligonucleotide Synthesis Linkers include Agilent Technologies, Inc, ATDBio Ltd, Bio-Synthesis Inc, BioAutomation, LGC Biosearch Technologies, Sarepta Therapeutics, Kaneka Corporation, GeneDesign, Inc and General Electric, etc. in 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Oligonucleotide Synthesis Linkers, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oligonucleotide Synthesis Linkers.
The Oligonucleotide Synthesis Linkers market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Oligonucleotide Synthesis Linkers market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oligonucleotide Synthesis Linkers manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Agilent Technologies, Inc
ATDBio Ltd
Bio-Synthesis Inc
BioAutomation
LGC Biosearch Technologies
Sarepta Therapeutics
Kaneka Corporation
GeneDesign, Inc
General Electric
GenScript
Integrated DNA Technologies, Inc
NITTO DENKO CORPORATION
Thermo Fisher Scientific, Inc
TriLink BioTechnologies
Danaher
Maravai LifeSciences
Biogen
Eurofins Scientific
Merck KGaA
Huzhou Hippo Biotechnology Co., Ltd.
Segment by Type
Single-Ended Index Connector
Double-Ended Index Connector
Segment by Application
Molecular Detection
Genetic Diagnosis
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Oligonucleotide Synthesis Linkers manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Oligonucleotide Synthesis Linkers in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Oligonucleotide Synthesis Linkers Market Overview
1.1 Product Overview and Scope of Oligonucleotide Synthesis Linkers
1.2 Oligonucleotide Synthesis Linkers Segment by Type
1.2.1 Global Oligonucleotide Synthesis Linkers Market Value Comparison by Type (2023-2029)
1.2.2 Single-Ended Index Connector
1.2.3 Double-Ended Index Connector
1.3 Oligonucleotide Synthesis Linkers Segment by Application
1.3.1 Global Oligonucleotide Synthesis Linkers Market Value by Application: (2023-2029)
1.3.2 Molecular Detection
1.3.3 Genetic Diagnosis
1.3.4 Other
1.4 Global Oligonucleotide Synthesis Linkers Market Size Estimates and Forecasts
1.4.1 Global Oligonucleotide Synthesis Linkers Revenue 2018-2029
1.4.2 Global Oligonucleotide Synthesis Linkers Sales 2018-2029
1.4.3 Global Oligonucleotide Synthesis Linkers Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Oligonucleotide Synthesis Linkers Market Competition by Manufacturers
2.1 Global Oligonucleotide Synthesis Linkers Sales Market Share by Manufacturers (2018-2023)
2.2 Global Oligonucleotide Synthesis Linkers Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Oligonucleotide Synthesis Linkers Average Price by Manufacturers (2018-2023)
2.4 Global Oligonucleotide Synthesis Linkers Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Oligonucleotide Synthesis Linkers, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Oligonucleotide Synthesis Linkers, Product Type & Application
2.7 Oligonucleotide Synthesis Linkers Market Competitive Situation and Trends
2.7.1 Oligonucleotide Synthesis Linkers Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Oligonucleotide Synthesis Linkers Players Market Share by Revenue
2.7.3 Global Oligonucleotide Synthesis Linkers Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Oligonucleotide Synthesis Linkers Retrospective Market Scenario by Region
3.1 Global Oligonucleotide Synthesis Linkers Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Oligonucleotide Synthesis Linkers Global Oligonucleotide Synthesis Linkers Sales by Region: 2018-2029
3.2.1 Global Oligonucleotide Synthesis Linkers Sales by Region: 2018-2023
3.2.2 Global Oligonucleotide Synthesis Linkers Sales by Region: 2024-2029
3.3 Global Oligonucleotide Synthesis Linkers Global Oligonucleotide Synthesis Linkers Revenue by Region: 2018-2029
3.3.1 Global Oligonucleotide Synthesis Linkers Revenue by Region: 2018-2023
3.3.2 Global Oligonucleotide Synthesis Linkers Revenue by Region: 2024-2029
3.4 North America Oligonucleotide Synthesis Linkers Market Facts & Figures by Country
3.4.1 North America Oligonucleotide Synthesis Linkers Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Oligonucleotide Synthesis Linkers Sales by Country (2018-2029)
3.4.3 North America Oligonucleotide Synthesis Linkers Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Oligonucleotide Synthesis Linkers Market Facts & Figures by Country
3.5.1 Europe Oligonucleotide Synthesis Linkers Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Oligonucleotide Synthesis Linkers Sales by Country (2018-2029)
3.5.3 Europe Oligonucleotide Synthesis Linkers Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Oligonucleotide Synthesis Linkers Market Facts & Figures by Country
3.6.1 Asia Pacific Oligonucleotide Synthesis Linkers Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Oligonucleotide Synthesis Linkers Sales by Country (2018-2029)
3.6.3 Asia Pacific Oligonucleotide Synthesis Linkers Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Oligonucleotide Synthesis Linkers Market Facts & Figures by Country
3.7.1 Latin America Oligonucleotide Synthesis Linkers Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Oligonucleotide Synthesis Linkers Sales by Country (2018-2029)
3.7.3 Latin America Oligonucleotide Synthesis Linkers Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Oligonucleotide Synthesis Linkers Market Facts & Figures by Country
3.8.1 Middle East and Africa Oligonucleotide Synthesis Linkers Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Oligonucleotide Synthesis Linkers Sales by Country (2018-2029)
3.8.3 Middle East and Africa Oligonucleotide Synthesis Linkers Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Oligonucleotide Synthesis Linkers Sales by Type (2018-2029)
4.1.1 Global Oligonucleotide Synthesis Linkers Sales by Type (2018-2023)
4.1.2 Global Oligonucleotide Synthesis Linkers Sales by Type (2024-2029)
4.1.3 Global Oligonucleotide Synthesis Linkers Sales Market Share by Type (2018-2029)
4.2 Global Oligonucleotide Synthesis Linkers Revenue by Type (2018-2029)
4.2.1 Global Oligonucleotide Synthesis Linkers Revenue by Type (2018-2023)
4.2.2 Global Oligonucleotide Synthesis Linkers Revenue by Type (2024-2029)
4.2.3 Global Oligonucleotide Synthesis Linkers Revenue Market Share by Type (2018-2029)
4.3 Global Oligonucleotide Synthesis Linkers Price by Type (2018-2029)
5 Segment by Application
5.1 Global Oligonucleotide Synthesis Linkers Sales by Application (2018-2029)
5.1.1 Global Oligonucleotide Synthesis Linkers Sales by Application (2018-2023)
5.1.2 Global Oligonucleotide Synthesis Linkers Sales by Application (2024-2029)
5.1.3 Global Oligonucleotide Synthesis Linkers Sales Market Share by Application (2018-2029)
5.2 Global Oligonucleotide Synthesis Linkers Revenue by Application (2018-2029)
5.2.1 Global Oligonucleotide Synthesis Linkers Revenue by Application (2018-2023)
5.2.2 Global Oligonucleotide Synthesis Linkers Revenue by Application (2024-2029)
5.2.3 Global Oligonucleotide Synthesis Linkers Revenue Market Share by Application (2018-2029)
5.3 Global Oligonucleotide Synthesis Linkers Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Agilent Technologies, Inc
6.1.1 Agilent Technologies, Inc Corporation Information
6.1.2 Agilent Technologies, Inc Description and Business Overview
6.1.3 Agilent Technologies, Inc Oligonucleotide Synthesis Linkers Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Agilent Technologies, Inc Oligonucleotide Synthesis Linkers Product Portfolio
6.1.5 Agilent Technologies, Inc Recent Developments/Updates
6.2 ATDBio Ltd
6.2.1 ATDBio Ltd Corporation Information
6.2.2 ATDBio Ltd Description and Business Overview
6.2.3 ATDBio Ltd Oligonucleotide Synthesis Linkers Sales, Revenue and Gross Margin (2018-2023)
6.2.4 ATDBio Ltd Oligonucleotide Synthesis Linkers Product Portfolio
6.2.5 ATDBio Ltd Recent Developments/Updates
6.3 Bio-Synthesis Inc
6.3.1 Bio-Synthesis Inc Corporation Information
6.3.2 Bio-Synthesis Inc Description and Business Overview
6.3.3 Bio-Synthesis Inc Oligonucleotide Synthesis Linkers Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Bio-Synthesis Inc Oligonucleotide Synthesis Linkers Product Portfolio
6.3.5 Bio-Synthesis Inc Recent Developments/Updates
6.4 BioAutomation
6.4.1 BioAutomation Corporation Information
6.4.2 BioAutomation Description and Business Overview
6.4.3 BioAutomation Oligonucleotide Synthesis Linkers Sales, Revenue and Gross Margin (2018-2023)
6.4.4 BioAutomation Oligonucleotide Synthesis Linkers Product Portfolio
6.4.5 BioAutomation Recent Developments/Updates
6.5 LGC Biosearch Technologies
6.5.1 LGC Biosearch Technologies Corporation Information
6.5.2 LGC Biosearch Technologies Description and Business Overview
6.5.3 LGC Biosearch Technologies Oligonucleotide Synthesis Linkers Sales, Revenue and Gross Margin (2018-2023)
6.5.4 LGC Biosearch Technologies Oligonucleotide Synthesis Linkers Product Portfolio
6.5.5 LGC Biosearch Technologies Recent Developments/Updates
6.6 Sarepta Therapeutics
6.6.1 Sarepta Therapeutics Corporation Information
6.6.2 Sarepta Therapeutics Description and Business Overview
6.6.3 Sarepta Therapeutics Oligonucleotide Synthesis Linkers Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Sarepta Therapeutics Oligonucleotide Synthesis Linkers Product Portfolio
6.6.5 Sarepta Therapeutics Recent Developments/Updates
6.7 Kaneka Corporation
6.6.1 Kaneka Corporation Corporation Information
6.6.2 Kaneka Corporation Description and Business Overview
6.6.3 Kaneka Corporation Oligonucleotide Synthesis Linkers Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Kaneka Corporation Oligonucleotide Synthesis Linkers Product Portfolio
6.7.5 Kaneka Corporation Recent Developments/Updates
6.8 GeneDesign, Inc
6.8.1 GeneDesign, Inc Corporation Information
6.8.2 GeneDesign, Inc Description and Business Overview
6.8.3 GeneDesign, Inc Oligonucleotide Synthesis Linkers Sales, Revenue and Gross Margin (2018-2023)
6.8.4 GeneDesign, Inc Oligonucleotide Synthesis Linkers Product Portfolio
6.8.5 GeneDesign, Inc Recent Developments/Updates
6.9 General Electric
6.9.1 General Electric Corporation Information
6.9.2 General Electric Description and Business Overview
6.9.3 General Electric Oligonucleotide Synthesis Linkers Sales, Revenue and Gross Margin (2018-2023)
6.9.4 General Electric Oligonucleotide Synthesis Linkers Product Portfolio
6.9.5 General Electric Recent Developments/Updates
6.10 GenScript
6.10.1 GenScript Corporation Information
6.10.2 GenScript Description and Business Overview
6.10.3 GenScript Oligonucleotide Synthesis Linkers Sales, Revenue and Gross Margin (2018-2023)
6.10.4 GenScript Oligonucleotide Synthesis Linkers Product Portfolio
6.10.5 GenScript Recent Developments/Updates
6.11 Integrated DNA Technologies, Inc
6.11.1 Integrated DNA Technologies, Inc Corporation Information
6.11.2 Integrated DNA Technologies, Inc Oligonucleotide Synthesis Linkers Description and Business Overview
6.11.3 Integrated DNA Technologies, Inc Oligonucleotide Synthesis Linkers Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Integrated DNA Technologies, Inc Oligonucleotide Synthesis Linkers Product Portfolio
6.11.5 Integrated DNA Technologies, Inc Recent Developments/Updates
6.12 NITTO DENKO CORPORATION
6.12.1 NITTO DENKO CORPORATION Corporation Information
6.12.2 NITTO DENKO CORPORATION Oligonucleotide Synthesis Linkers Description and Business Overview
6.12.3 NITTO DENKO CORPORATION Oligonucleotide Synthesis Linkers Sales, Revenue and Gross Margin (2018-2023)
6.12.4 NITTO DENKO CORPORATION Oligonucleotide Synthesis Linkers Product Portfolio
6.12.5 NITTO DENKO CORPORATION Recent Developments/Updates
6.13 Thermo Fisher Scientific, Inc
6.13.1 Thermo Fisher Scientific, Inc Corporation Information
6.13.2 Thermo Fisher Scientific, Inc Oligonucleotide Synthesis Linkers Description and Business Overview
6.13.3 Thermo Fisher Scientific, Inc Oligonucleotide Synthesis Linkers Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Thermo Fisher Scientific, Inc Oligonucleotide Synthesis Linkers Product Portfolio
6.13.5 Thermo Fisher Scientific, Inc Recent Developments/Updates
6.14 TriLink BioTechnologies
6.14.1 TriLink BioTechnologies Corporation Information
6.14.2 TriLink BioTechnologies Oligonucleotide Synthesis Linkers Description and Business Overview
6.14.3 TriLink BioTechnologies Oligonucleotide Synthesis Linkers Sales, Revenue and Gross Margin (2018-2023)
6.14.4 TriLink BioTechnologies Oligonucleotide Synthesis Linkers Product Portfolio
6.14.5 TriLink BioTechnologies Recent Developments/Updates
6.15 Danaher
6.15.1 Danaher Corporation Information
6.15.2 Danaher Oligonucleotide Synthesis Linkers Description and Business Overview
6.15.3 Danaher Oligonucleotide Synthesis Linkers Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Danaher Oligonucleotide Synthesis Linkers Product Portfolio
6.15.5 Danaher Recent Developments/Updates
6.16 Maravai LifeSciences
6.16.1 Maravai LifeSciences Corporation Information
6.16.2 Maravai LifeSciences Oligonucleotide Synthesis Linkers Description and Business Overview
6.16.3 Maravai LifeSciences Oligonucleotide Synthesis Linkers Sales, Revenue and Gross Margin (2018-2023)
6.16.4 Maravai LifeSciences Oligonucleotide Synthesis Linkers Product Portfolio
6.16.5 Maravai LifeSciences Recent Developments/Updates
6.17 Biogen
6.17.1 Biogen Corporation Information
6.17.2 Biogen Oligonucleotide Synthesis Linkers Description and Business Overview
6.17.3 Biogen Oligonucleotide Synthesis Linkers Sales, Revenue and Gross Margin (2018-2023)
6.17.4 Biogen Oligonucleotide Synthesis Linkers Product Portfolio
6.17.5 Biogen Recent Developments/Updates
6.18 Eurofins Scientific
6.18.1 Eurofins Scientific Corporation Information
6.18.2 Eurofins Scientific Oligonucleotide Synthesis Linkers Description and Business Overview
6.18.3 Eurofins Scientific Oligonucleotide Synthesis Linkers Sales, Revenue and Gross Margin (2018-2023)
6.18.4 Eurofins Scientific Oligonucleotide Synthesis Linkers Product Portfolio
6.18.5 Eurofins Scientific Recent Developments/Updates
6.19 Merck KGaA
6.19.1 Merck KGaA Corporation Information
6.19.2 Merck KGaA Oligonucleotide Synthesis Linkers Description and Business Overview
6.19.3 Merck KGaA Oligonucleotide Synthesis Linkers Sales, Revenue and Gross Margin (2018-2023)
6.19.4 Merck KGaA Oligonucleotide Synthesis Linkers Product Portfolio
6.19.5 Merck KGaA Recent Developments/Updates
6.20 Huzhou Hippo Biotechnology Co., Ltd.
6.20.1 Huzhou Hippo Biotechnology Co., Ltd. Corporation Information
6.20.2 Huzhou Hippo Biotechnology Co., Ltd. Oligonucleotide Synthesis Linkers Description and Business Overview
6.20.3 Huzhou Hippo Biotechnology Co., Ltd. Oligonucleotide Synthesis Linkers Sales, Revenue and Gross Margin (2018-2023)
6.20.4 Huzhou Hippo Biotechnology Co., Ltd. Oligonucleotide Synthesis Linkers Product Portfolio
6.20.5 Huzhou Hippo Biotechnology Co., Ltd. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Oligonucleotide Synthesis Linkers Industry Chain Analysis
7.2 Oligonucleotide Synthesis Linkers Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Oligonucleotide Synthesis Linkers Production Mode & Process
7.4 Oligonucleotide Synthesis Linkers Sales and Marketing
7.4.1 Oligonucleotide Synthesis Linkers Sales Channels
7.4.2 Oligonucleotide Synthesis Linkers Distributors
7.5 Oligonucleotide Synthesis Linkers Customers
8 Oligonucleotide Synthesis Linkers Market Dynamics
8.1 Oligonucleotide Synthesis Linkers Industry Trends
8.2 Oligonucleotide Synthesis Linkers Market Drivers
8.3 Oligonucleotide Synthesis Linkers Market Challenges
8.4 Oligonucleotide Synthesis Linkers Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Agilent Technologies, Inc
ATDBio Ltd
Bio-Synthesis Inc
BioAutomation
LGC Biosearch Technologies
Sarepta Therapeutics
Kaneka Corporation
GeneDesign, Inc
General Electric
GenScript
Integrated DNA Technologies, Inc
NITTO DENKO CORPORATION
Thermo Fisher Scientific, Inc
TriLink BioTechnologies
Danaher
Maravai LifeSciences
Biogen
Eurofins Scientific
Merck KGaA
Huzhou Hippo Biotechnology Co., Ltd.
听
听
*If Applicable.
